시장보고서

상품코드

1671160

세계의 말라리아 백신 시장 규모, 점유율, 동향, 업계 분석 : 백신 종류별, 투여 경로별, 대상 인구별, 예방 접종 스케줄별, 개발 단계별, 지역별 - 시장 예측(2025-2034년)

Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route, Target Population, Immunization Schedule, Development Stage, and Region - Market Forecast, 2025-2034

발행일: 2025년 02월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 114 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 말라리아 백신 시장 규모는 2034년까지 16억 1,987만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

말라리아는 감염된 모기에 물려 사람에서 사람으로 전염되는 원충에 의해 발생하는 생명을 위협하는 심각한 질병입니다. 모기가 매개하는 이 질병은 어린이와 성인에게 심각한 질병을 유발합니다. 특히 임산부와 어린이는 말라리아로 인한 발열에 취약합니다. 이 질병을 예방하기 위한 다양한 예방책으로는 방충망 사용, 살충제 살포 등이 있습니다. 그러나 현재 조사 연구에 따르면 곤충은 살충제에 면역이 있고, 살충제는 인체에 해로운 영향을 미치며, 말라리아 열은 약이 듣지 않는 것으로 밝혀지고 있습니다. 이에 따라 연구자들과 제약회사들은 대체 예방법으로 말라리아 백신을 개발하기 위해 노력하고 있습니다.

전 세계 말라리아 발병률의 증가와 제약회사들의 저가형 말라리아 백신 출시 등 여러 요인들이 말라리아 백신 시장의 성장을 촉진하고 있습니다. 말라리아의 영향에 대한 인식이 높아지고 연구개발(R&D)에 대한 지속적인 노력이 시장 개척을 더욱 촉진하고 있습니다.

일부 말라리아가 유행하는 개발도상국의 취약한 공급망 및 유통망 문제를 해결하기 위한 정부 기관 및 민간 단체의 개발 증가는 말라리아 백신의 채택을 촉진할 것으로 예상됩니다. 예방접종 프로그램의 증가와 혁신적인 백신 기술 개발에 대한 강조는 향후 몇 년 동안 말라리아 백신 시장에 몇 가지 시장 기회를 제공할 것으로 예상됩니다.

말라리아 백신 시장 : 분석 개요

백신 유형별로는 RTS, S/AS01 백신의 효능을 입증하는 광범위한 임상 연구 및 임상시험과 아프리카 국가에서의 개발로 인해 RTS, S/AS01 분야가 2024년 말라리아 백신 시장 매출에서 가장 큰 비중을 차지했습니다.

투여 경로별로는 R21/Matrix-M, RTS, S/AS01을 포함한 말라리아 백신의 투여에 근육 내 투여가 가장 널리 사용되어 2024년 말라리아 백신 시장 점유율은 근육 내 투여가 주도했습니다.

북미는 말라리아 백신 개발 프로그램에 많은 투자를 하고 있는 주요 제약사들의 강력한 존재감과 말라리아 백신 R&D 이니셔티브를 지원하는 유리한 정부 규제 도입으로 인해 2024년 말라리아 백신 시장을 주도했습니다.

중동 및 아프리카의 말라리아 백신 시장은 2025년부터 2034년까지 상당한 CAGR을 기록할 것으로 예상됩니다. 이는 의료 인프라 구축에 대한 관심 증가와 비용 효율적인 말라리아 백신 개발을 위한 정부 및 민간 조직 간의 협력 강화에 기인합니다.

Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company는 이 시장의 주요 기업 중 하나입니다.

시장 현황
말라리아 백신 시장 역학
- 성장 촉진요인과 기회
  - 저소득국의 말라리아 만연 확대
  - 자금과 투자 증가
- 성장 억제요인과 과제
  - 의약품 개발과 유통에 소요되는 고비용
PESTLE 분석
말라리아 백신 시장 응용 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 말라리아 백신 시장 : 백신 종류별

주요 분석 결과
소개
PfSPZ
RTS,S/AS01　
R21/Matrix-M

제6장 세계의 말라리아 백신 시장 : 투여 경로별

주요 분석 결과
소개
피하
근육내

제7장 세계의 말라리아 백신 시장 : 대상 인구별

주요 분석 결과
소개
유행 지역 여행자
임산부
5세 미만 소아

제8장 세계의 말라리아 백신 시장 : 예방 접종 스케줄별

주요 분석 결과
소개
일회 접종
다회 접종
추가 접종

제9장 세계의 말라리아 백신 시장 : 개발 단계별

주요 분석 결과
소개
전임상
임상시험

제10장 세계의 말라리아 백신 시장 : 지역별

주요 분석 결과
소개
- 말라리아 백신 시장 평가 : 지역별(2020-2034년)
북미
- 북미 : 백신 종류별(2020-2034년)
- 북미 : 투여 경로별(2020-2034년)
- 북미 : 대상 인구별(2020-2034년)
- 북미 : 예방 접종 스케줄별(2020-2034년)
- 북미 : 개발 단계별(2020-2034년)
- 미국
- 캐나다
유럽
- 유럽 : 백신 종류별(2020-2034년)
- 유럽 : 투여 경로별(2020-2034년)
- 유럽 : 대상 인구별(2020-2034년)
- 유럽 : 예방 접종 스케줄별(2020-2034년)
- 유럽 : 개발 단계별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 백신 종류별(2020-2034년)
- 아시아태평양 : 투여 경로별(2020-2034년)
- 아시아태평양 : 대상 인구별(2020-2034년)
- 아시아태평양 : 예방 접종 스케줄별(2020-2034년)
- 아시아태평양 : 개발 단계별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 백신 종류별(2020-2034년)
- 중동 및 아프리카 : 투여 경로별(2020-2034년)
- 중동 및 아프리카 : 대상 인구별(2020-2034년)
- 중동 및 아프리카 : 예방 접종 스케줄별(2020-2034년)
- 중동 및 아프리카 : 개발 단계별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 백신 종류별(2020-2034년)
- 라틴아메리카 : 투여 경로별(2020-2034년)
- 라틴아메리카 : 대상 인구별(2020-2034년)
- 라틴아메리카 : 예방 접종 스케줄별(2020-2034년)
- 라틴아메리카 : 개발 단계별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제11장 경쟁 구도

사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
제휴/협업/합의/공개

제12장 기업 개요

Instituto Butantan
Merck
PATH
GSK
Vaxart
Biovac
Pfizer
Inovio Pharmaceuticals
Bharat Biotech
University of Oxford
Intellia Therapeutics
Johnson & Johnson
Sanaria
Takeda Pharmaceutical Company

ksm 25.04.01

The global malaria vaccines market size is expected to reach USD 1,619.87 million by 2034, according to a new study by Polaris Market Research. The report "Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route (Subcutaneous and Intramuscular), Target Population, Immunization Schedule, Development Stage, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Malaria is a serious, life-threatening disease caused by Plasmodium parasite, which is transmitted from human to human by the bite of infected mosquitoes. This mosquito-borne illness causes severe disease in kids and adults. Pregnant women and children are particularly vulnerable to the fever caused by malaria. Various precautions to control the disease include the use of insect nets and spraying of pesticides. However, current research studies have shown that insects are immune to pesticides, pesticides have harmful effects on human beings, and malaria fever is becoming immune to medications. In response to these challenges, researchers and pharmaceutical companies have been working on the development of malaria vaccines as an alternative method of prevention.

Several factors, such as the rising incidence of malaria worldwide and the introduction of low-cost malaria vaccines by pharma companies globally, are driving the malaria vaccines market growth. Rising awareness about the disease's consequences and ongoing research and development (R&D) initiatives are further supporting the market development.

Growing efforts by government and private organizations to address the issues of weak supply chains and distribution networks in some malaria-endemic developing countries are expected to boost the adoption of malaria vaccines. Rising inoculation programs and emphasis on the development of innovative vaccine technologies are expected to provide several malaria vaccines market opportunities in the coming years.

Key Highlights of Malaria Vaccines Market Report

Based on vaccine type, the RTS,S/AS01 segment held the largest share of the malaria vaccines market revenue in 2024, owing to the extensive clinical research and trials demonstrating the efficacy of RTS, S/AS01 vaccines, and their rollout in various African countries.

By administration route, the intramuscular segment led the malaria vaccines market share in 2024 as intramuscular is the most widely used route for administrating malaria vaccines, including R21/Matrix-M and RTS,S/AS01.

North America led the market for malaria vaccines in 2024, driven by the strong presence of leading pharma companies with significant investments in malaria vaccine development programs and the introduction of favorable government regulations supporting malaria vaccine R&D initiatives.

The Middle East & Africa malaria vaccines market is projected to witness a significant CAGR from 2025 to 2034, driven by the rising focus on improving healthcare infrastructure and enhanced collaborations between government and private organizations to develop cost-effective malaria vaccines.

Polaris Market Research has segmented the malaria vaccines market research report on the basis of vaccine type, administration route, target population, immunization schedule, development stage, and region:

By Vaccine Type Outlook (Revenue - USD Million, 2020-2034)

PfSPZ
RTS,S/AS01
R21/Matrix-M

By Administration Route Outlook (Revenue - USD Million, 2020-2034)

Subcutaneous
Intramuscular

By Target Population Outlook (Revenue - USD Million, 2020-2034)

Travelers to Endemic Areas
Pregnant Women
Children under 5 Years

By Immunization Schedule Outlook (Revenue - USD Million, 2020-2034)

Single Dose
Multi-Dose
Booster Doses

By Development Stage Outlook (Revenue - USD Million, 2020-2034)

Preclinical
Clinical Trials

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Malaria Vaccines Market Insights

4.1. Malaria Vaccines Market - Application Snapshot
4.2. Malaria Vaccines Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Growing Prevalence of Malaria in Low-Income Countries
  - 4.2.1.2. Increasing Funding and Investment
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost of Drug Development and Distribution
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry Among Existing Firms (High)
4.4. PESTEL Analysis
4.5. Malaria Vaccines Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Malaria Vaccines Market, by Vaccine Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
5.3. PfSPZ
- 5.3.1. Global Malaria Vaccines Market, by PfSPZ, by Region, 2020-2034 (USD Million)
5.4. RTS,S/AS01
- 5.4.1. Global Malaria Vaccines Market, by RTS,S/AS01, by Region, 2020-2034 (USD Million)
5.5. R21/Matrix-M
- 5.5.1. Global Malaria Vaccines Market, by R21/Matrix-M, by Region, 2020-2034 (USD Million)

6. Global Malaria Vaccines Market, by Administration Route

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
6.3. Subcutaneous
- 6.3.1. Global Malaria Vaccines Market, by Subcutaneous, by Region, 2020-2034 (USD Million)
6.4. Intramuscular
- 6.4.1. Global Malaria Vaccines Market, by Intramuscular, by Region, 2020-2034 (USD Million)

7. Global Malaria Vaccines Market, by Target Population

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
7.3. Travelers to Endemic Areas
- 7.3.1. Global Malaria Vaccines Market, by Travelers to Endemic Areas, by Region, 2020-2034 (USD Million)
7.4. Pregnant Women
- 7.4.1. Global Malaria Vaccines Market, by Pregnant Women, by Region, 2020-2034 (USD Million)
7.5. Children Under 5 years
- 7.5.1. Global Malaria Vaccines Market, by Children Under 5 years, by Region, 2020-2034 (USD Million)

8. Global Malaria Vaccines Market, by Immunization Schedule

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
8.3. Single Dose
- 8.3.1. Global Malaria Vaccines Market, by Single Dose, by Region, 2020-2034 (USD Million)
8.4. Multi-Dose
- 8.4.1. Global Malaria Vaccines Market, by Multi-Dose, by Region, 2020-2034 (USD Million)
8.5. Booster Doses
- 8.5.1. Global Malaria Vaccines Market, by Booster Doses, by Region, 2020-2034 (USD Million)

9. Global Malaria Vaccines Market, by Development Stage

9.1. Key Findings
9.2. Introduction
- 9.2.1. Global Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
9.3. Preclinical
- 9.3.1. Global Malaria Vaccines Market, by Preclinical, by Region, 2020-2034 (USD Million)
9.4. Clinical Trials
- 9.4.1. Global Malaria Vaccines Market, by Clinical Trials, by Region, 2020-2034 (USD Million)

10. Global Malaria Vaccines Market, by Geography

10.1. Key Findings
10.2. Introduction
- 10.2.1. Malaria Vaccines Market Assessment, by Geography, 2020-2034 (USD Million)
10.3. Malaria Vaccines Market - North America
- 10.3.1. North America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
- 10.3.2. North America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
- 10.3.3. North America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
- 10.3.4. North America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
- 10.3.5. North America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.3.6. Malaria Vaccines Market - US
  - 10.3.6.1. US: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.3.6.2. US: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.3.6.3. US: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.3.6.4. US: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.3.6.5. US: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.3.7. Malaria Vaccines Market - Canada
  - 10.3.7.1. Canada: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.3.7.2. Canada: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.3.7.3. Canada: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.3.7.4. Canada: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.3.7.5. Canada: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.4. Malaria Vaccines Market - Europe
- 10.4.1. Europe: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
- 10.4.2. Europe: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
- 10.4.3. Europe: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
- 10.4.4. Europe: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
- 10.4.5. Europe: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.6. Malaria Vaccines Market - UK
  - 10.4.6.1. UK: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.6.2. UK: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.6.3. UK: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.6.4. UK: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.6.5. UK: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.7. Malaria Vaccines Market - France
  - 10.4.7.1. France: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.7.2. France: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.7.3. France: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.7.4. France: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.7.5. France: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.8. Malaria Vaccines Market - Germany
  - 10.4.8.1. Germany: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.8.2. Germany: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.8.3. Germany: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.8.4. Germany: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.8.5. Germany: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.9. Malaria Vaccines Market - Italy
  - 10.4.9.1. Italy: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.9.2. Italy: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.9.3. Italy: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.9.4. Italy: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.9.5. Italy: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.10. Malaria Vaccines Market - Spain
  - 10.4.10.1. Spain: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.10.2. Spain: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.10.3. Spain: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.10.4. Spain: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.10.5. Spain: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.11. Malaria Vaccines Market - Netherlands
  - 10.4.11.1. Netherlands: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.11.2. Netherlands: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.11.3. Netherlands: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.11.4. Netherlands: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.11.5. Netherlands: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.12. Malaria Vaccines Market - Russia
  - 10.4.12.1. Russia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.12.2. Russia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.12.3. Russia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.12.4. Russia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.12.5. Russia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.4.13. Malaria Vaccines Market - Rest of Europe
  - 10.4.13.1. Rest of Europe: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.4.13.2. Rest of Europe: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.4.13.3. Rest of Europe: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.4.13.4. Rest of Europe: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.4.13.5. Rest of Europe: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.5. Malaria Vaccines Market - Asia Pacific
- 10.5.1. Asia Pacific: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
- 10.5.2. Asia Pacific: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
- 10.5.3. Asia Pacific: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
- 10.5.4. Asia Pacific: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
- 10.5.5. Asia Pacific: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.6. Malaria Vaccines Market - China
  - 10.5.6.1. China: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.6.2. China: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.6.3. China: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.6.4. China: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.6.5. China: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.7. Malaria Vaccines Market - India
  - 10.5.7.1. India: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.7.2. India: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.7.3. India: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.7.4. India: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.7.5. India: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.8. Malaria Vaccines Market - Malaysia
  - 10.5.8.1. Malaysia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.8.2. Malaysia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.8.3. Malaysia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.8.4. Malaysia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.8.5. Malaysia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.9. Malaria Vaccines Market - Japan
  - 10.5.9.1. Japan: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.9.2. Japan: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.9.3. Japan: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.9.4. Japan: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.9.5. Japan: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.10. Malaria Vaccines Market - Indonesia
  - 10.5.10.1. Indonesia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.10.2. Indonesia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.10.3. Indonesia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.10.4. Indonesia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.10.5. Indonesia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.11. Malaria Vaccines Market - South Korea
  - 10.5.11.1. South Korea: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.11.2. South Korea: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.11.3. South Korea: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.11.4. South Korea: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.11.5. South Korea: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.12. Malaria Vaccines Market - Australia
  - 10.5.12.1. Australia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.12.2. Australia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.12.3. Australia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.12.4. Australia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.12.5. Australia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.5.13. Malaria Vaccines Market - Rest of Asia Pacific
  - 10.5.13.1. Rest of Asia Pacific: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.5.13.2. Rest of Asia Pacific: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.5.13.3. Rest of Asia Pacific: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.5.13.4. Rest of Asia Pacific: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.5.13.5. Rest of Asia Pacific: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.6. Malaria Vaccines Market - Middle East & Africa
- 10.6.1. Middle East & Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
- 10.6.2. Middle East & Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
- 10.6.3. Middle East & Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
- 10.6.4. Middle East & Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
- 10.6.5. Middle East & Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.6.6. Malaria Vaccines Market - Saudi Arabia
  - 10.6.6.1. Saudi Arabia: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.6.6.2. Saudi Arabia: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.6.6.3. Saudi Arabia: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.6.6.4. Saudi Arabia: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.6.6.5. Saudi Arabia: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.6.7. Malaria Vaccines Market - UAE
  - 10.6.7.1. UAE: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.6.7.2. UAE: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.6.7.3. UAE: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.6.7.4. UAE: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.6.7.5. UAE: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.6.8. Malaria Vaccines Market - Israel
  - 10.6.8.1. Israel: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.6.8.2. Israel: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.6.8.3. Israel: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.6.8.4. Israel: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.6.8.5. Israel: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.6.9. Malaria Vaccines Market - South Africa
  - 10.6.9.1. South Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.6.9.2. South Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.6.9.3. South Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.6.9.4. South Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.6.9.5. South Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.6.10. Malaria Vaccines Market - Rest of Middle East & Africa
  - 10.6.10.1. Rest of Middle East & Africa: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.6.10.2. Rest of Middle East & Africa: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.6.10.3. Rest of Middle East & Africa: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.6.10.4. Rest of Middle East & Africa: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.6.10.5. Rest of Middle East & Africa: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
10.7. Malaria Vaccines Market - Latin America
- 10.7.1. Latin America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
- 10.7.2. Latin America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
- 10.7.3. Latin America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
- 10.7.4. Latin America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
- 10.7.5. Latin America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.7.6. Malaria Vaccines Market - Mexico
  - 10.7.6.1. Mexico: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.7.6.2. Mexico: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.7.6.3. Mexico: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.7.6.4. Mexico: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.7.6.5. Mexico: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.7.7. Malaria Vaccines Market - Brazil
  - 10.7.7.1. Brazil: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.7.7.2. Brazil: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.7.7.3. Brazil: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.7.7.4. Brazil: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.7.7.5. Brazil: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.7.8. Malaria Vaccines Market - Argentina
  - 10.7.8.1. Argentina: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.7.8.2. Argentina: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.7.8.3. Argentina: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.7.8.4. Argentina: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.7.8.5. Argentina: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)
- 10.7.9. Malaria Vaccines Market - Rest of Latin America
  - 10.7.9.1. Rest of Latin America: Malaria Vaccines Market, by Vaccine Type, 2020-2034 (USD Million)
  - 10.7.9.2. Rest of Latin America: Malaria Vaccines Market, by Administration Route, 2020-2034 (USD Million)
  - 10.7.9.3. Rest of Latin America: Malaria Vaccines Market, by Target Population, 2020-2034 (USD Million)
  - 10.7.9.4. Rest of Latin America: Malaria Vaccines Market, by Immunization Schedule, 2020-2034 (USD Million)
  - 10.7.9.5. Rest of Latin America: Malaria Vaccines Market, by Development Stage, 2020-2034 (USD Million)

11. Competitive Landscape

11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

12.1. Instituto Butantan
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
12.2. Merck
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
12.3. PATH
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
12.4. GSK
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
12.5. Vaxart
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
12.6. Biovac
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
12.7. Pfizer
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
12.8. Inovio Pharmaceuticals
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
12.9. Bharat Biotech
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
12.10. University of Oxford
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development
12.11. Intellia Therapeutics
- 12.11.1. Company Overview
- 12.11.2. Financial Performance
- 12.11.3. Product Benchmarking
- 12.11.4. Recent Development
12.12. Johnson & Johnson
- 12.12.1. Company Overview
- 12.12.2. Financial Performance
- 12.12.3. Product Benchmarking
- 12.12.4. Recent Development
12.13. Sanaria
- 12.13.1. Company Overview
- 12.13.2. Financial Performance
- 12.13.3. Product Benchmarking
- 12.13.4. Recent Development
12.14. Takeda Pharmaceutical Company
- 12.14.1. Company Overview
- 12.14.2. Financial Performance
- 12.14.3. Product Benchmarking
- 12.14.4. Recent Development